Ovarian Cancer Coverage from Every Angle

Elizabeth H. Stover, MD, PhD, on Nivolumab and Bevacizumab: Genomic Biomarker Analysis of an Ovarian Cancer Regimen

Posted: Wednesday, September 2, 2020

Elizabeth H. Stover, MD, PhD, of Dana-Farber Cancer Institute, discusses her phase II study of treatment with nivolumab plus bevacizumab and the next steps needed to identify genomic or transcriptomic biomarkers of responses to checkpoint blockade and antiangiogenic therapy for ovarian cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.